Browse drugs

…umab) are often used in ovarian and cervical cancers. ICIs (eg, pembrolizumab) are effective in mismatch repair-deficient endometrial cancer …

…TEZO, atezolizumab; BINI, binimetinib; COBI, cobimetinib; ENCO, encorafenib; ESS, effective sample size; DAB, dabrafenib; NIVO, nivolumab; …

…non-diabetic controls. Inhibition of MEK1/2-ERK1/2 pathway with trametinib resulted in significant reduction in the generation of mROS in …

…lls demonstrated significant ERK phosphorylation reduction with trametinib (IC 50=12.3 nM) and sotorasib (IC50=38.7 nM).Conclusions This s…

…d OS of 13.4 months,38 39 leading to full FDA approval in 2024. Adagrasib has also shown modest activity in PDAC (ORR 33%, PFS 5.4 months…

…suggesting that DC inclusion dampens the macrophage response to bemcentinib.9 Separation of macrophages by A375 state was further reflected…

…), atezolizumab (Tecentriq), osimertinib (Tagrisso), ceritinib (Zykadia) and nintedanib (Vargatef). EMA labels for all products include…

…participation in the trial. Standard therapies considered were: pembrolizumab (adjuvant, high risk stage II–IV melanoma); dabrafenib + tramet…

…f care (26.3%). 31.5% of patients required a dose adjustment of binimetinib, and 21% discontinued treatment, with only one discontinuation …

…(NIVO+RELA) to BRAF/MEK inhibitors, we compared its efficacy to dabrafenib+trametinib (DAB+TRAM), encorafenib+binimetinib (ENCO+BINI), vem…

…05755Thomas SS, Gogas H, Hong YK, et al. Efficacy and safety of lifileucel, an autologous tumor-infiltrating lymphocyte cell therapy, and …